NCT03063086View on ClinicalTrials.gov

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

January 21, 2017

Primary Completion Date

August 2, 2018

Study Completion Date

August 2, 2018

Conditions
Asthma
Interventions
DRUG

QVM149 150/50/80 μg o.d.

A

DRUG

QVM149 150/50/160 μg o.d.

B

DRUG

salmeterol/fluticasone FDC 50/500 μg b.i.d.

C

Trial Locations (12)

1612

Novartis Investigative Site, Sofia

9713

Novartis Investigative Site, Groningen

10117

Novartis Investigative Site, Berlin

22947

Novartis Investigative Site, Großhansdorf

30625

Novartis Investigative Site, Hanover

60596

Novartis Investigative Site, Frankfurt

65187

Novartis Investigative Site, Wiesbaden

130021

Novartis Investigative Site, Changchun

200433

Novartis Investigative Site, Shanghai

300192

Novartis Investigative Site, Tianjin

Unknown

Novartis Investigative Site, Bucharest

M23 9QZ

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY